Senator Investment Group LP Sells 10,000 Shares of Novo Nordisk A/S (NYSE:NVO)

Senator Investment Group LP reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 10.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 90,000 shares of the company’s stock after selling 10,000 shares during the quarter. Senator Investment Group LP’s holdings in Novo Nordisk A/S were worth $7,742,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of NVO. Tower Research Capital LLC TRC grew its holdings in Novo Nordisk A/S by 27.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 12,621 shares of the company’s stock worth $1,086,000 after acquiring an additional 2,688 shares during the period. Transatlantique Private Wealth LLC lifted its stake in Novo Nordisk A/S by 10.4% in the fourth quarter. Transatlantique Private Wealth LLC now owns 6,811 shares of the company’s stock valued at $586,000 after buying an additional 640 shares during the period. Transce3nd LLC bought a new position in Novo Nordisk A/S during the fourth quarter worth about $33,000. Kelly Lawrence W & Associates Inc. CA bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $39,000. Finally, MML Investors Services LLC boosted its stake in Novo Nordisk A/S by 1.9% during the 4th quarter. MML Investors Services LLC now owns 274,230 shares of the company’s stock worth $23,589,000 after acquiring an additional 4,983 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $57.99 on Monday. The stock has a market capitalization of $260.23 billion, a PE ratio of 17.63, a P/E/G ratio of 0.90 and a beta of 0.61. Novo Nordisk A/S has a fifty-two week low of $57.28 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The business has a fifty day moving average price of $75.52 and a two-hundred day moving average price of $91.38.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date was Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.54%.

Wall Street Analyst Weigh In

NVO has been the subject of a number of recent analyst reports. BNP Paribas started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an “underperform” rating for the company. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 15th. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, BMO Capital Markets reiterated a “market perform” rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $135.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.